Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Abbott
ClinicalTrials.gov Identifier:
NCT00555204
First received: November 7, 2007
Last updated: August 19, 2011
Last verified: August 2011
  Purpose

The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.


Condition Intervention Phase
Alzheimer's Disease
Drug: ABT-089
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Study Using a Bayesian Adaptive Design to Evaluate the Efficacy and Safety of ABT-089 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Resource links provided by NLM:


Further study details as provided by Abbott:

Primary Outcome Measures:
  • Safety and Tolerability [ Time Frame: Baseline to Final Evaluation ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetics (how the body handles the study drug) [ Time Frame: Baseline to Final Evaluation ] [ Designated as safety issue: No ]
  • Pharmacodynamic (how the study drug affects cognitive functions such as thinking and memory) [ Time Frame: Baseline to Final Evaluation ] [ Designated as safety issue: No ]

Enrollment: 337
Study Start Date: November 2007
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: ABT-089
5 mg - capsules once daily for 12 weeks
Experimental: B Drug: ABT-089
10 mg - capsules once daily for 12 weeks
Experimental: C Drug: ABT-089
15 mg - capsules once daily for 12 weeks
Experimental: D Drug: ABT-089
20 mg - capsules once daily for 12 weeks
Experimental: E Drug: ABT-089
30 mg - capsules once daily for 12 weeks
Experimental: F Drug: ABT-089
35 mg - capsules once daily for 12 weeks
Placebo Comparator: G Drug: placebo
placebo - capsules once daily for 12 weeks

  Eligibility

Ages Eligible for Study:   55 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient has mild to moderate Alzheimer's disease
  • Patient has been receiving a stable dose of an acetylcholinesterase inhibitor
  • Patient has a MMSE score between 12 and 26
  • Patient has a MHIS score of less than or equal to 4
  • Females must be postmenopausal for at least two years or surgically sterile
  • Patient has an identified, reliable, caregiver who will support him/her to ensure compliance with treatment and will accompany them to each outpatient visit

Exclusion Criteria:

  • Patient is living in a nursing home
  • Patient has a history of any significant neurologic disease other than Alzheimer's disease
  • Patient has any uncontrolled medical illness
  • Patient uses non-prescribed drugs of abuse or has a history of drug or alcohol abuse/dependence
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00555204

  Hide Study Locations
Locations
United States, Arizona
Phoenix, Arizona, United States, 85006
Sun City, Arizona, United States, 85351
United States, California
Fresno, California, United States, 93720
San Diego, California, United States, 92108
Santa Ana, California, United States, 92705
Santa Monica, California, United States, 90404
United States, Connecticut
Hamden, Connecticut, United States, 06518
New Haven, Connecticut, United States, 06510
United States, Florida
Brooksville, Florida, United States, 34613
Delray Beach, Florida, United States, 33445
Fort Myers, Florida, United States, 33901
Hallendale, Florida, United States, 33009
Hialeah, Florida, United States, 33016
Largo, Florida, United States, 33770
Miami, Florida, United States, 33180
Palm Beach Gardens, Florida, United States, 33418
Sunrise, Florida, United States, 33351
Tampa, Florida, United States, 33613
West Palm Beach, Florida, United States, 33407
West Palm Beach, Florida, United States, 33409
United States, Indiana
Indianapolis, Indiana, United States, 46260
United States, Kentucky
Paducah, Kentucky, United States, 42003
United States, Massachusetts
Pittsfield, Massachusetts, United States, 01201
United States, Michigan
Grand Rapids, Michigan, United States, 49503
United States, Missouri
St Louis, Missouri, United States, 63141
United States, New Jersey
Long Branch, New Jersey, United States, 07740
Nutley, New Jersey, United States, 07110
Princeton, New Jersey, United States, 08540
Ridgewood, New Jersey, United States, 07450
United States, New York
Albany, New York, United States, 12208
Bronx, New York, United States, 10454
New York, New York, United States, 10021
Staten Island, New York, United States, 10312
United States, North Carolina
Hickory, North Carolina, United States, 28601
Winston-Salem, North Carolina, United States, 27104
United States, Ohio
Centerville, Ohio, United States, 45459
Cleveland, Ohio, United States, 44106
United States, Pennsylvania
Jenkintown, Pennsylvania, United States, 19046
Norristown, Pennsylvania, United States, 19401
United States, Texas
San Antonio, Texas, United States, 78229
Wichita Falls, Texas, United States, 76309
United States, Vermont
Bennington, Vermont, United States, 05201
Sponsors and Collaborators
Abbott
Investigators
Study Director: Robert Lenz, MD, PhD Abbott
  More Information

No publications provided

Responsible Party: Abbott
ClinicalTrials.gov Identifier: NCT00555204     History of Changes
Other Study ID Numbers: M06-876
Study First Received: November 7, 2007
Last Updated: August 19, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Abbott:
mild to moderate Alzheimer's disease, memory, cognition, dementia

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 17, 2014